OncoMatch/Clinical Trials/NCT05623982
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Is NCT05623982 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies GNC-038 for non-hodgkin's lymphoma.
Treatment: GNC-038 — To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received:
Patients with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL)
Cannot have received: autologous hematopoietic stem cell transplantation
Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before initiating GNC-038 treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
Cannot have received: CAR-T cell therapy
CAR-T therapy within 12 weeks before initiating GNC-038 treatment
Cannot have received: radiation therapy
Radiotherapy within 4 weeks before initiating GNC-038 treatment
Cannot have received: chemotherapy
Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment
Cannot have received: small-molecule targeted therapy
Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives prior to treatment
Cannot have received: investigational drug
Use of any other investigational drug in a clinical trial within 4 weeks or 5 half-lives before the first dose of this study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05623982 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplantation, allogeneic hematopoietic stem cell transplantation, CAR-T cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages